Japan Non-opioid Pain Treatment Market Size & Outlook, 2030

Revenue, 2024 (US$M)

$0.0

Forecast, 2030 (US$M)

$0.0

CAGR, 2025 - 2030

Report Coverage

Japan

Japan non-opioid pain treatment market, 2018-2030 (US$M)

Related Markets

Global Non-opioid Pain Treatment Industry Outlook

North America Non-opioid Pain Treatment Market Outlook

Europe Non-opioid Pain Treatment Market Outlook

Asia Pacific Non-opioid Pain Treatment Market Outlook

Latin America Non-opioid Pain Treatment Market Outlook

MEA Non-opioid Pain Treatment Market Outlook

Japan non-opioid pain treatment market highlights

The Japan non-opioid pain treatment market generated a revenue of USD 1,910.5 million in 2021 and is expected to reach USD 4,606.9 million by 2030.
The Japan market is expected to grow at a CAGR of 10.3% from 2022 to 2030.
In terms of segment, local anesthetics was the largest revenue generating drug class in 2021.
Acetaminophen is the most lucrative drug class segment registering the fastest growth during the forecast period.

Non-opioid pain treatment market data book summary

Market revenue in 2021	USD 1,910.5 million
Market revenue in 2030	USD 4,606.9 million
Growth rate	10.3% (CAGR from 2021 to 2030)
Largest segment	Local anesthetics
Fastest growing segment	Acetaminophen
Historical data	2018 - 2020
Base year	2021
Forecast period	2022 - 2030
Quantitative units	Revenue in USD million
Market segmentation	NSAIDs, Acetaminophen, Local Anesthetics
Key market players worldwide	Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, GSK PLC ADR, Pfizer Inc, Perrigo Co PLC, LNK International Inc., Cipla Ltd DR, Johnson & Johnson, Pacira BioSciences Inc, Pierrel S.p.A

Other key industry trends

In terms of revenue, Japan accounted for 4.9% of the global non-opioid pain treatment market in 2021.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Asia Pacific, China non-opioid pain treatment market is projected to lead the regional market in terms of revenue in 2030.
India is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,059.1 million by 2030.

Key Regions: U.S. , UK , Brazil , UAE , Canada

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Non-opioid Pain Treatment Market Scope

Non-opioid pain treatment market segmentation & scope

Drug Class

NSAIDs

Selective COX-2 Inhibitors

Non-Selective NSAIDs

Acetaminophen

Local Anesthetics

Others

Pain Type

Chronic Pain

Neuropathic Pain

Inflammatory Conditions

Post-operative Pain

Cancer Pain

Others

Route of Administration

Oral

Topical

Injectable

Others

Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Others

Regions

Latin America

Europe

North America

Middle East & Africa

Asia Pacific

Countries

U.S.

Canada

Mexico

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Japan

China

India

Australia

South Korea

Thailand

Brazil

Argentina

South Africa

Saudi Arabia

UAE

Kuwait

Non-opioid Pain Treatment Market Companies

Name	Profile	# Employees	HQ	Website

Japan non-opioid pain treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-opioid pain treatment market will help companies and investors design strategic landscapes.

Local anesthetics was the largest segment with a revenue share of 43.65% in 2024. Horizon Databook has segmented the Japan non-opioid pain treatment market based on nsaids, acetaminophen, local anesthetics covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Japan non-opioid pain treatment market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan non-opioid pain treatment market databook

Our clientele includes a mix of non-opioid pain treatment market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan non-opioid pain treatment market , including forecasts for subscribers. This country databook contains high-level insights into Japan non-opioid pain treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list